Distribution of antidiabetic medication use in a cohort of 66 778 women with type 2 diabetes
| Antidiabetic medication | N | Per cent |
|---|---|---|
| Metformin | ||
| Metformin only | 4887 | 7.32 |
| Metformin combinations | ||
| Metformin+sulfonylureas only | 11 193 | 16.76 |
| Metformin+insulin only | 655 | 0.98 |
| Metformin+other non-metformin drugs* | 10 189 | 15.26 |
| Non-metformin | ||
| Sulfonylureas only | 8253 | 12.36 |
| Insulin only | 4705 | 7.05 |
| Other non-metformin drugs* | 1907 | 2.86 |
| Non-antidiabetic medication users | 24 989 | 37.42 |
| Total | 66 778 | |
*Exposed to one or more of these classes: α-glucosidase inhibitors; amylinomimetics; biguanides; dipeptidyl peptidase-4 inhibitors; incretin mimetics; insulin; meglitinides; sulfonylureas; thiazolidinediones (glitazones).